Axsome Therapeutics (AXSM) Research & Development (2015 - 2026)

Axsome Therapeutics' Research & Development history runs 12 years deep, the most recent figure standing at $52.7 million for Q1 2026.

• In Q1 2026, Research & Development rose 17.62% year-over-year to $52.7 million; the TTM figure through Mar 2026 stood at $145.0 million (down 25.66% YoY), while the FY2025 annual figure was $183.3 million, down 2.03% from the prior year.
• Research & Development came in at $52.7 million for Q1 2026 at Axsome Therapeutics, up from $2.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $55.0 million in Q4 2024 to a low of $2.6 million in Q4 2025.
• A 5-year average of $31.3 million and a median of $30.8 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 142.23% in 2024 and tumbled 95.27% in 2025, its largest moves.
• Axsome Therapeutics' Research & Development stood at $14.7 million in 2022, then surged by 109.64% to $30.8 million in 2023, then surged by 78.57% to $55.0 million in 2024, then sank by 95.27% to $2.6 million in 2025, then soared by 1926.04% to $52.7 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $52.7 million, $2.6 million, and $40.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison